John Xu
Directeur Général chez Jemincare Therapeutics Corp.
Profil
John Xu is the founder and Chief Executive Officer of Jemincare Therapeutics Corp.
which is founded in 2018.
He was also a Senior Vice President of Strategic Alliances at Abpro Corp.
from 2017 to 2019.
Dr. Xu holds a doctorate from Zhongshan Hospital Fudan University, a graduate degree from Chicago Medical School, and an MBA from the University of Colorado Colorado Springs.
Postes actifs de John Xu
| Sociétés | Poste | Début |
|---|---|---|
Jemincare Therapeutics Corp.
 Jemincare Therapeutics Corp. BiotechnologyHealth Technology Jemincare Therapeutics Corp. is a pharmaceutical company. It plans to in license the global and China rights of the large and small molecule clinical stage programs in therapeutic areas such as oncology, cardiovascular and kidney disease. The company was founded by John Xu in November 2018 and is headquartered in Princeton, NJ. | Directeur Général | 01/11/2018 |
Anciens postes connus de John Xu
| Sociétés | Poste | Fin |
|---|---|---|
| ABPRO CORPORATION | Corporate Officer/Principal | - |
Formation de John Xu
| Zhongshan Hospital Fudan University | Doctorate Degree |
| Chicago Medical School | Graduate Degree |
| University of Colorado Colorado Springs | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Abpro Corp.
 Abpro Corp. BiotechnologyHealth Technology Abpro Corp. operates as a biotechnology company which develops antibody therapeutics for severe and life threatening diseases. It focusses on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. The company was founded by Ian Chan and Eugene Y. Chan in 2007 and is headquartered in Woburn, MA. | Health Technology |
Jemincare Therapeutics Corp.
Jemincare Therapeutics Corp. BiotechnologyHealth Technology Jemincare Therapeutics Corp. is a pharmaceutical company. It plans to in license the global and China rights of the large and small molecule clinical stage programs in therapeutic areas such as oncology, cardiovascular and kidney disease. The company was founded by John Xu in November 2018 and is headquartered in Princeton, NJ. | Health Technology |
